Top
image credit: Adobe Stock

bluebird bio sells second FDA priority review voucher for $95m

January 9, 2023

Via: PMLiVE
Category:

The company’s first voucher was sold for $102m to Dutch biotech Argenx, which expected to use the PRV for a future marketing application for efgartigimod, its first-in-class neonatal Fc receptor blocker.

The Rare Pediatric Disease PRV programme was created to encourage the development of new drug and biological products for the prevention and treatment of certain rare paediatric diseases.

As part of the programme, upon approval, the US Food and Drug Administration (FDA) awards PRVs to sponsors of rare paediatric disease product applications that meet a specific set of criteria. The voucher can be used for a priority review of any drug, or it can be sold or transferred to another company.

Read More on PMLiVE